The “bad cholesterol” test doesn’t tell the whole story

For decades, evaluation Cholesterol risk is built around a simple idea: lower your “bad” cholesterol, and reduce your chance of having a heart attack. The test at the heart of this approach measures how much low-density lipoprotein, or bad cholesterol, is circulating in a portion of the blood. It has helped shape everything from clinical guidelines to the widespread use of statins, drugs that reduce low-density lipoprotein (LDL).

It works. Lowering LDL cholesterol reduces heart attacks, strokes, and premature death. But it doesn’t tell the whole story.

An LDL cholesterol test measures the amount of cholesterol within low-density lipoprotein particles circulating in the bloodstream. LDL particles that contain cholesterol can get trapped in the walls of your arteries, forming plaques that can eventually block blood flow. Since the test measures the amount of cholesterol carried, not the number of LDL particles themselves, two people can have the same LDL cholesterol level but with very different numbers of particles, and therefore different levels of risk.

This gap has pushed researchers toward a different way of measuring risk. Apolipoprotein B, or apoB, reflects the total number of cholesterol-carrying molecules in the blood, not the amount of cholesterol it contains. A growing body of research suggests it is a more accurate way to determine who is at risk and who is not.

In March 2026, the American Heart Association and the American College of Cardiology recognized this. Their updated cholesterol guidelines recognized apoB as a potentially more accurate marker, in line with previous European recommendations. But they stopped short of recommending apoB as the primary method of testing.

“They review the evidence and rate ApoB as superior, but the actual rules of the road continue to prioritize LDL,” says Alan Snyderman, MD, a cardiologist at McGill University.

Snyderman was an author of a 2026 JAMA modeling study that analyzed lifetime outcomes for about 250,000 American adults eligible for statin treatment. Comparing LDL cholesterol, non-HDL cholesterol, and apoB, the study found that using apoB to guide treatment decisions would prevent more heart attacks and strokes than current methods, while remaining cost-effective.

ApoB testing can be done through standard blood tests. So why is it not recommended in routine care? Not even in Europe, where guidelines have reflected their usefulness for years.

Part of the answer is inertia. For decades, LDL cholesterol has been a scientific breakthrough and a public health success story. It is simple, widely understood, and directly linked to successful treatments.

“For 50 years, LDL cholesterol has been an amazing discovery,” says Snyderman. “Not that it’s not a good sign. It’s a good sign.”

Borg Nordestgaard, president of the European Atherosclerosis Society, agrees that LDL cholesterol remains essential for a reason. “The evidence is overwhelming,” he says, “and it is beyond discussion.” “Statins reduce heart attacks, strokes, and premature death by lowering bad cholesterol.”

This success has helped shape a powerful narrative that low-density lipoprotein (LDL) is “bad cholesterol,” and lowering it saves lives. But this simplicity also limited how risks were understood.

“The result is that patients and doctors know little or nothing about apoB,” says Snyderman.

Recent research suggests that the cholesterol picture is more complex, especially in people who already take statins. Previous studies by Nordestgaard have shown that in treated patients, high levels of lipoprotein B and non-HDL cholesterol remain associated with an increased risk of heart attacks and mortality, while LDL cholesterol is not. ApoB, in particular, emerged as the most accurate marker.

For Kausik Ray, a cardiologist at Imperial College London, the challenge is not to choose one marker over another, but to understand what each marker captures, and what it misses.

“We’re not interested in cholesterol per se,” Ray says. “We’re trying to prevent heart attacks and strokes.”